Slide 1: Third Quarter 2025 Financial Results & Business Update
Third Quarter 2025 Financial Results & Business Update October 28, 2025
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkerm
Slide 3: Q3 2025 Financial and Operational Performance
Q3 2025 Financial and Operational Performance
Slide 4: Q3 2025 Financial Results Summary
Q3 2025 Financial Results Summary Total Revenue GAAP Net Income GAAP Earnings Per Share Diluted In millions In millions $394.2 $378.1 $0.55 $92.4 $82.8 $0.49 Q3 2024 Q3 2025 Q3 2024 Q3 2025 Q3 2024 Q3 2025 Q3 2025 results reflect expiration of royalty on U.S. net sales of INVEGA SUSTENNA® in August
Slide 5: Q3 2025 Profitability
Q3 2025 Profitability GAAP Net Income EBITDA* Adjusted EBITDA* From Continuing Operations From Continuing Operations In millions In millions In millions $112.3 $134.3 $92.8 $96.9 $121.5 $82.8 Q3 2024 Q3 2025 Q3 2024 Q3 2025 Q3 2024 Q3 2025 EBITDA represents earnings before interest, tax, depreciatio
Slide 6: Q3 2025 Revenue Summary
Q3 2025 Revenue Summary In millions Q3’25 Q3’24 Total Proprietary Net Sales $317.4 $273.0 VIVITROL® $121.1 $113.7 ARISTADA®* $98.1 $84.7 LYBALVI® $98.2 $74.7 Manufacturing & Royalty Revenue $76.8** $105.1** Total Revenue $394.2** $378.1** Amounts in the table may not sum due to rounding. *Inclusive
Slide 7: Alkermes: 2025 Financial Expectations
Alkermes: 2025 Financial Expectations Previous Financial Updated Financial (in millions) Expectations for Year Expectations for Year Ending Dec. 31, 2025 Ending Dec. 31, 2025* (provided Feb. 12, 2025) (provided Oct. 28, 2025) Total Revenues $1,340 – $1,430 $1,430 – $1,490 Expected net sales of propr
Slide 8: Q3 2025 Commercial Review
Q3 2025 Commercial Review
Slide 9: LYBALVI Performance and Expectations
LYBALVI® Performance and Expectations LYBALVI Quarterly Net Sales ($M) $100 Q3’25 LYBALVI net sales of $98.2M reflects 32% growth compared to Q3’24 $90 $80 • Q3’25 gross-to-net deductions: ~28% $70 Outlook: $60 • FY’25 net sales expected to range from $50 $340M – $350M* $40 $30 $20 $10 $0 Q1'23 Q2'2
Slide 10: ARISTADA Performance and Expectations
ARISTADA® Performance and Expectations ARISTADA Quarterly Net Sales* ($M) $110 Q3’25 ARISTADA net sales were $98.1M $100 Outlook: $90 • FY’25 net sales expected to range from $80 $360M – $370M†* $70 $60 $50 $40 $30 $20 $10 $0 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 *Inclusi
Slide 11: VIVITROL Performance and Expectations
VIVITROL® Performance and Expectations VIVITROL Quarterly Net Sales ($M) $140 Q3’25 VIVITROL net sales were $121.1M $120 Outlook: • FY’25 net sales expected to range from $100 $460M – $470M* $80 $60 $40 $20 $0 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 *These expectations are
Slide 12: Appendix
Appendix
Slide 13: Appendix: Amounts Included in Discontinued Operations
Appendix: Amounts Included in Discontinued Operations Three Months Ended (In thousands) September 30, 2024 Cost of goods manufactured and sold $ -- Research and development 481 Selling, general and administrative --- Income tax benefit $ (67) Loss from discontinued operations, net of tax $ 414 13 ©
Slide 14: Appendix: Financial Results GAAP to Non-GAAP Reconciliation
Appendix: Financial Results GAAP to Non-GAAP Reconciliation Three Months Ended Three Months Ended (In millions) September 30, 2025 September 30, 2024 Net Income from Continuing Operations — GAAP $ 82.8 $ 92.8 Adjustments: Depreciation expense 8.1 7.0 Amortization expense 0.0 0.0 Interest income (11.
Slide 15: Appendix: Financial Expectations GAAP to Non-GAAP Reconciliation
Appendix: Financial Expectations GAAP to Non-GAAP Reconciliation Year Ending (In millions) December 31, 2025 Projected Net Income — GAAP $ 240.0 Adjustments: Interest income (40.0) Depreciation and amortization expense 30.0 Provision for income taxes 50.0 Projected EBTIDA $ 280.0 Shared-based compen
Slide 16: www.alkermes.com
www.alkermes.com © 2025 Alkermes. All rights reserved.